Analyst Price Targets — MESO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 24, 2024 8:07 am | Jason McCarthy | Maxim Group | $12.00 | $6.74 | TheFly | Mesoblast upgraded to Buy at Maxim on Ryoncil opportunity |
| July 23, 2024 1:06 pm | Edward Tenthoff | Piper Sandler | $11.00 | $8.27 | StreetInsider | Piper Sandler Upgrades Mesoblast Limited (MESO) to Overweight |
Latest News for MESO
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical
Mesoblast Limited (NASDAQ: MESO - Get Free Report)'s stock price gapped down before the market opened on Friday. The stock had previously closed at $16.92, but opened at $15.80. Mesoblast shares last traded at $15.87, with a volume of 179,801 shares. Wall Street Analyst Weigh In Separately, Weiss Ratings reiterated a "sell (e+)" rating on
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
Financial Results and Operational Update for Half-Year Ended December 31, 2025 Financial Results and Operational Update for Half-Year Ended December 31, 2025
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025. The webcast will begin at 5.00pm EST, Thursday, February 26; 9.00am AEDT, Friday, February 27, 2026.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for MESO.
Senate Trading
No Senate trades found for MESO.
U.S. House Trading
No House trades found for MESO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.